These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33558663)

  • 1. Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer.
    Amori G; Sugawara E; Shigematsu Y; Akiya M; Kunieda J; Yuasa T; Yamamoto S; Yonese J; Takeuchi K; Inamura K
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):767-774. PubMed ID: 33558663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis.
    Benzon B; Zhao SG; Haffner MC; Takhar M; Erho N; Yousefi K; Hurley P; Bishop JL; Tosoian J; Ghabili K; Alshalalfa M; Glavaris S; Simons BW; Tran P; Davicioni E; Karnes RJ; Boudadi K; Antonarakis ES; Schaeffer EM; Drake CG; Feng F; Ross AE
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):28-35. PubMed ID: 27801901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High B7-H3 expression is linked to increased risk of prostate cancer progression.
    Bonk S; Tasdelen P; Kluth M; Hube-Magg C; Makrypidi-Fraune G; Möller K; Höflmayer D; Dwertmann Rico S; Büscheck F; Minner S; Heinzer H; Graefen M; Hinsch A; Luebke AM; Dum D; Uhlig R; Schlomm T; Sauter G; Simon R; Weidemann SA
    Pathol Int; 2020 Oct; 70(10):733-742. PubMed ID: 32776718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
    Nunes-Xavier CE; Kildal W; Kleppe A; Danielsen HE; Waehre H; Llarena R; Maelandsmo GM; Fodstad Ø; Pulido R; López JI
    Prostate; 2021 Sep; 81(12):838-848. PubMed ID: 34125445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
    Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
    Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
    [No Abstract]   [Full Text] [Related]  

  • 6. Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population?
    Liu Y; Vlatkovic L; Sæter T; Servoll E; Waaler G; Nesland JM; Giercksky KE; Axcrona K
    Int J Urol; 2012 Aug; 19(8):749-56. PubMed ID: 22487487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies.
    Miller CD; Lozada JR; Zorko NA; Elliott A; Makovec A; Radovich M; Heath EI; Agarwal N; Mckay RR; Garje R; Bastos BR; Hoon DSB; Orme JJ; Sartor O; VanderWalde A; Nabhan C; Sledge G; Shenderov E; Dehm SM; Lou E; Miller JS; Hwang JH; Antonarakis ES
    Cancer Res Commun; 2024 May; 4(5):1369-1379. PubMed ID: 38709075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B7-H3 promotes the proliferation, migration and invasiveness of cervical cancer cells and is an indicator of poor prognosis.
    Li Y; Zhang J; Han S; Qian Q; Chen Q; Liu L; Zhang Y
    Oncol Rep; 2017 Aug; 38(2):1043-1050. PubMed ID: 28627681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy.
    Yang S; Wei W; Zhao Q
    Int J Biol Sci; 2020; 16(11):1767-1773. PubMed ID: 32398947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells.
    Zhang Y; He L; Sadagopan A; Ma T; Dotti G; Wang Y; Zheng H; Gao X; Wang D; DeLeo AB; Fan S; Sun R; Yu L; Zhang L; Wang G; Ferrone S; Wang X
    Mol Cancer Ther; 2021 Mar; 20(3):577-588. PubMed ID: 33653946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma.
    Deng J; Ma M; Wang D; Zhu H; Hua L; Sun S; Chen H; Cheng H; Qian ZR; Xie Q; Zhang T; Gong Y
    World Neurosurg; 2020 Mar; 135():e12-e18. PubMed ID: 31629137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer.
    Yim J; Koh J; Kim S; Song SG; Ahn HK; Kim YA; Jeon YK; Chung DH
    Eur J Cancer; 2020 Jul; 133():74-85. PubMed ID: 32447027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical correlation of B7-H3 and B3GALT4 with the prognosis of colorectal cancer.
    Zhang T; Wang F; Wu JY; Qiu ZC; Wang Y; Liu F; Ge XS; Qi XW; Mao Y; Hua D
    World J Gastroenterol; 2018 Aug; 24(31):3538-3546. PubMed ID: 30131660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies.
    Shi W; Wang Y; Zhao Y; Kim JJ; Li H; Meng C; Chen F; Zhang J; Mak DH; Van V; Leo J; St Croix B; Aparicio A; Zhao D
    Sci Transl Med; 2023 May; 15(695):eadf6724. PubMed ID: 37163614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B7-H3: a robust target for immunotherapy in prostate cancer.
    Pulido R; López JI; Nunes-Xavier CE
    Trends Cancer; 2024 Jul; 10(7):584-587. PubMed ID: 38839545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?
    Malapelle U; Parente P; Pepe F; Di Micco MC; Russo A; Clemente C; Graziano P; Rossi A
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor B7-H3 (CD276) Expression and Survival in Pancreatic Cancer.
    Inamura K; Takazawa Y; Inoue Y; Yokouchi Y; Kobayashi M; Saiura A; Shibutani T; Ishikawa Y
    J Clin Med; 2018 Jul; 7(7):. PubMed ID: 29996538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-H3 Promotes Prostate Cancer Progression in Mice by Antagonizing Myeloid-Derived Suppressor Cell Apoptosis.
    Zhou Y; Zhang G; Zhang W; Wei X; Hou J; Huang Y
    Technol Cancer Res Treat; 2020; 19():1533033820971649. PubMed ID: 33280506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B7-H3 on circulating epithelial tumor cells correlates with the proliferation marker, Ki-67, and may be associated with the aggressiveness of tumors in breast cancer patients.
    Pizon M; Schott DS; Pachmann U; Pachmann K
    Int J Oncol; 2018 Nov; 53(5):2289-2299. PubMed ID: 30226585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases.
    Chavin G; Sheinin Y; Crispen PL; Boorjian SA; Roth TJ; Rangel L; Blute ML; Sebo TJ; Tindall DJ; Kwon ED; Karnes RJ
    Clin Cancer Res; 2009 Mar; 15(6):2174-80. PubMed ID: 19276267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.